Logo
x

Search

Subscribe Now

Innovent Biologics

The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC

The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC

  • August 22, 2024
Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

  • May 9, 2024
Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)

Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)

  • May 7, 2024
Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease

Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease

  • February 20, 2024
Innovent Biologics Enters into a Collaboration Agreement with Xuanzhu Biopharma to Study and Supply Tyvyt with KM-501 for Solid Tumors

Innovent Biologics Enters into a Collaboration Agreement with Xuanzhu Biopharma to Study and Supply Tyvyt with KM-501 for Solid Tu...

  • December 28, 2023
Innovent Biologics Signs an Expanded Agreement with Synaffix for the Development of Antibody Drug Conjugates (ADCs)

Innovent Biologics Signs an Expanded Agreement with Synaffix for the Development of Antibody Drug Conjugates (ADCs)

  • December 7, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.